- Posts: 100
- Thank you received: 3
1. You must be a registered website user in order to post and comment. Guests may read only.
2. Be kind and helpful, not rude and cynical.
3. Don't advertise or promote anything. You will be banned from the group.
4. Report problems to the moderators. THANK YOU!
Sandy Too wrote: I can't be trying any second line drug, suggested rituximab, if I can end up with even more infections.
www.iwmf.com/sites/default/files/docs/Rituximab-Associated_Infections-Seminars_in_Hematology.pdf
Rituximab-Associated Infections
After more than 10 years of use, rituximab has proven to be remarkably safe. However,
accumulated evidence now suggests that under some circumstances it may significantly
increase the risk of infections. This risk is difficult to quantify because of confounding factors
(namely, concomitant use of immunosuppressive or chemotherapeutic agents and underlying
conditions), as well as under-reporting. Increased number of infections has been documented
in patients treated with maintenance rituximab for low-grade lymphoma and in patients with
concomitant severe immunodeficiency, whether caused by human immunodeficiency virus
(HIV) infection or immunosuppressive agents like fludarabine. From the practical standpoint,
the most important infection is hepatitis B reactivation, which may be delayed and result in
fulminant liver failure and death. Special care should be placed on screening for hepatitis B
virus (HBV) and preemptive antiviral treatment. Some investigators have reported an increase
in Pneumocystis pneumonia. Finally, there is increasing evidence of a possible association with
progressive multifocal leukoencephalopathy (PML), a lethal encephalitis caused by the polyomavirus
JC. This review enumerates the described infectious complications, summarizes the
possible underlying mechanisms of the increased risk, and makes recommendations regarding
prevention, diagnosis and management.
Semin Hematol 47:187–198. © 2010 Published by Elsevier Inc.
The Platelet Disorder Support Association does not provide medical advice or endorse any medication, vitamins or herbs. The information contained herein is not intended nor implied to be a substitute for professional medical advice and is provided for educational purposes only. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment, discontinuing an existing treatment and to discuss any questions you may have regarding your unique medical condition.
Platelet Disorder Support Association
8751 Brecksville Road, Suite 150, Cleveland, Ohio 44141
Phone: 1-87-PLATELET | 877-528-3538 (toll free) | or 440-746-9003
E-mail: pdsa@pdsa.org
© Copyright 1997 - 2025, Platelet Disorder Support Association. All rights reserved.
The Platelet Disorder Support Association is a 501(c)3 organization and donations are tax deductible to the fullest extent allowed by law.